AMGN May 2024 275.000 put
| Previous close | 5.13 |
| Open | 4.90 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 275.00 |
| Expiry date | 2024-05-03 |
| Day's range | 4.90 - 6.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 326 |
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug. Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound.
ReutersFutures rise on Apple, Amgen boost; jobs data on tap
Apple jumped 5.8%, outpacing other megacap stocks in premarket trading after the iPhone maker unveiled a record $110 billion share buyback program and beat modest expectations for quarterly results and forecast. Amgen climbed 13.5% as the biotechnology firm said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide and as it reported first-quarter earnings. Sentiment also remained upbeat as investors weighed the U.S. Federal Reserve's more dovish-than-expected interest rate guidance in its latest policy meeting, causing U.S. stocks to rally on Thursday.
